Table.
Summary of included trials
| Standard trials (n=99) | Older-people trials (n=11) | Community comparison (SAIL; n=56 036) | ||
|---|---|---|---|---|
| Mean age or median of trial mean ages, years | 55·6 (53·7–57·0) | 73·1 (71·6–74·2) | 60·6 (13·9) | |
| Percentage of women | 45% (40–49) | 55% (52–55) | 50·3% | |
| Drug under investigation | ||||
| Angiotensin receptor blocker | 66 (67%) | 8 (73%) | .. | |
| Renin inhibitor | 33 (33%) | 3 (27%) | .. | |
| Comparison | ||||
| Placebo | 22 (22%) | 1 (9%) | .. | |
| Drug of different class | 77 (78%) | 10 (91%) | .. | |
| Phase | ||||
| 3 | 67 (68%) | 5 (45%) | .. | |
| 4 | 32 (32%) | 6 (55%) | .. | |
| Trial endpoint | ||||
| Hard | 1 (1%) | 2 (18%) | .. | |
| Soft | 98 (99%) | 9 (82%) | .. | |
| Trial sample size | 722 (474–1124) | 754 (388–884) | .. | |
| Trial follow-up, days | 63 (56–98) | 98 (56–252) | .. | |
Data are median (IQR), mean (SD), n (%), or %. Data for each trial are available online, including data on baseline blood pressure (four [36%] older-people trials and 46 [46%] standard trials), comorbidity status (three [27%] older-people trials and 37 [37%] standard trials), and ethnicity (two [18%] older-people trials and 39 [39%] standard trials). These are not summarised in this table due to the high proportion of missing data. SAIL=Secure Anonymised Information Linkage.